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ABSTRACT  
   
The effects of specific histone deacetylase inhibitors (HDACi) on 
transgene expression in combination with a novel polymer as a delivery vehicle 
are investigated in this research. Polymer vectors, although safer than viruses, are 
notorious for low levels of gene expression. In this investigation, the use of an 
emerging chemotherapeutic anti-cancer drug molecule, HDACi, was used to 
enhance the polymer-mediated gene expression. HDACi are capable of inhibiting 
deacetylation activities of histones and other non-histone proteins in the 
cytoplasm and nucleus, as well as increase transcriptional activities necessary for 
gene expression. In a prior study, a parallel synthesis and screening of polymers 
yielded a lead cationic polymer with high DNA-binding properties, and even 
more attractive, high transgene expressions. Previous studies showed the use of 
this polymer in conjunction with cytoplasmic HDACi significantly enhanced gene 
expression in PC3-PSMA prostate cancer cells. This led to the basis for the 
investigation presented in this thesis, but to use nuclear HDACi to potentially 
achieve similar results. The HDACi, HDACi_A, was a previously discovered lead 
drug that had potential to significantly enhance luciferase expression in PC3-
PSMA cells. The results of this study found that the 20:1 polymer:plasmid DNA 
weight ratio was effective with 1 μM and 2 μM HDACI_A concentrations, 
showing up to a 9-fold enhancement. This enhancement suggested that HDACi_A 
was effectively aiding transfection. While not an astounding enhancement, it is 
still interesting enough to investigate further. Cell viabilities need to be 
determined to supplement the results.  
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Chapter 1 
INTRODUCTION 
Prostate cancer was estimated to present in 240,890 new cases and cause 33,720 
deaths in 2011, making it a leading cancer-related cause of death (second to lung cancer) 
in males in the United States (Howlader et al., 2010).  While it can be treated adequately 
if caught early enough, there still exist the not uncommon possibilities that the cancer 
may be inoperable, unresponsive to current treatments, or even recur after initial 
treatments. The problem, thus, lies in not only the effectiveness of drug and treatment 
options for prostate cancer, but also in the quality of life for the patient. While 
conventional techniques have proven successful in the eradication of this disease, the side 
effects are detrimental to the patient (Madalinska et al., 2001).  Such major health risks 
arise from the high toxicity of the drugs and the higher doses needed to overcome their 
low efficacy nature (Fisher et al., 1999). In order to lessen these harmful health risks, a 
shift in alternative approaches to combat cancer has become exceedingly more prevalent 
in the last few decades.  Gene therapy, in particular, has become the primary approach to 
do just that. 
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Chapter 2 
BACKGROUND 
2.1 Gene Therapy 
 Gene therapy aims at correcting a disease at a genetic level in order to alter the 
particular cells that cause disease, implant a new gene to kill the disease, or change other 
cells in the body in order to fight the disease more efficiently (Mayo Clinic, 2010). It is 
basically the process of delivering exogenous nucleic acids to diseased cells, which has 
emerged as a unique process to treat diseases that are both acquired and genetic.  Recent 
studies have shown substantial progress in effective gene therapy that could prove its 
widespread use to treat diseases in the near future. Gene therapy in eye diseases has 
shown great success, for example. Recombinant adeno-associated virus vectors have a 
range of effects for retinal gene transfer, lentiviral vectors mediate efficient sustained 
expression in retinal pigment epithelium, corneal endothelium and trabecular meshwork, 
and even non-viral methods are used in improving gene transfer in the retina (Bainbridge, 
Tan, & Ali, 2006). More specifically, a recent study of canines with Leber congenital 
amaurosis (a severe inherited form of retinal degeneration that induces severe visual 
impairment that leads to blindness), found that 16 of 18 treated eyes showed rescue 
vision and improved retinal function, after treatment of a genetically altered recombinant 
adeno-associated viral vector (Annear et al., 2011).  Progress such as these show just how 
prospective gene therapy is for disease treatments. 
Gene therapy most often uses a genetically altered DNA (in viral methods) and 
the negatively charged plasmid DNA (pDNA). A plasmid DNA is a large macromolecule 
(3-15 kbp) that is capable of encoding for a specific gene that could express its 
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complement protein within a target cell via transcription. The major obstacles preventing 
delivery, however, are the biological barriers presented by the target cell. An adequate 
vehicle is essential to propel the plasmid DNA through the cell membrane (without 
succumbing to attack by the immune system), transport it through the cytoplasm, and 
finally facilitate it through the nuclear membrane to achieve efficient transcription and 
translation. Therefore, in order ensure optimal transfection of a gene, the optimal delivery 
system should be able to the following: bind and transport DNA to target cells, evade the 
body’s immune response, release DNA in the cytoplasm, transport DNA through the 
cytoplasm, and transfer DNA across the nucleus (Barua, 2011).  
2.2 Cancer Gene Therapy 
 The application of gene therapy in cancer diseases has been a rapidly growing 
research field since the first clinical trial was performed by Steven A. Rosenburg and R. 
Micahel Blaese’s group in 1990. Successful tumor regression in patients with metastatic 
melanoma was achieved in their study, which paved the way for future use of gene 
transfer in cancer therapies (Rosenberg et al., 1990). Over the past couple of decades, 
substantial progress has been made in this field, with about 65% of the approved 1644 
gene therapy clinical trials used to treat cancer (Edelstein, 2012).   
There are four phases of clinical trials, where phase I is screening for safety, 
phase II is establishing the testing protocol, phase III is final testing, and phase IV is post-
approval studies. Currently, phase I, phase II and a combination of phase I/II trails are the 
most common clinical trials conducted with gene therapy. Most of these gene therapy 
applications are in the primary stages of clinical trial, but show great promise towards the 
latter stages.  
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In order to achieve efficient gene delivery, an appropriate vector is necessary, as 
stated previously. Currently, the most commonly used vectors in clinical trials are viral, 
followed far behind by non-viral (Edelstein, 2012). However, these do not possess all the 
desirable properties of effective and safe delivery of transgenes to their target cells in 
large quantities. Yet, both types of vehicles have their unique set of advantages and 
disadvantages that determine their use in gene therapy.  
2.3 Viral Vectors 
Viral vectors are viruses that have evolved over time to specifically function as a 
vehicle to deliver genetic data into their hosts in order to replicate. This specialized 
evolution has made viruses the most efficient delivery system of genes and it is used by 
many researchers who thought that domesticating viruses was a feasible approach. Many 
viral vectors in current use are (in order of most abundant) adenovirus, retrovirus, 
vaccinia (pox) virus, adeno-associated virus (AAV), herpes simplex virus (HSV), and 
lentivirus (Edelstein, 2012). While they may be the most efficient vector, viruses pose 
major safety risks, primarily due to their high immunogenicity effect. This became a 
well-known problem when a young patient died in 1999 after being treated with 
adenoviral vectors in an effort to treat an inherited enzyme deficiency (Marshall, 1999). 
Again in 2002 and 2003, young children suffering from an X-linked SCID-XI syndrome 
were treated with a retroviral gene therapy and later developed leukemia as a result of the 
viral mutagenesis (Thomas, Ehrhardt, & Kay, 2003). Clinical trials, such as these, have 
demanded a shift away from the use of viral vectors, since gene therapy is aimed to 
provide an alternative to current detrimental anti-cancer methods, not induce more 
harmful side effects. Aside from posing major health risks, viral vectors have additional 
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drawbacks such as: low DNA load capacity, relatively expensive production, and 
difficulty to produce in mass quantities (Atkinson & Chalmers, 1010). Despite these 
implications, viruses still remain the most widely used vectors in over two-thirds of 
clinical gene therapy (Edelstein, 2012). 
2.4 Non-Viral Vectors 
Non-viral vectors, on the other hand, have no limitations with transgene load 
capacity and provide a safer alternative to viruses. However, non-viral vehicles are 
notorious for the low efficiency of target and delivery to specific tissues, and tend to 
invoke dose-dependent inflammatory responses (Zhao et al., 2003; Norman et al., 2000). 
Many non-viral vectors have been explored for use in gene delivery including cationic 
molecules of lipids (Wansungu & Hoekstra, 2006), polyamines (Osland & Kleppe, 1977), 
and polymers (Lungwitz et al., 2005) Such polymers are  capable of condensing DNA 
into complexes on a nanoscale level by neutralizing negative charges on DNA in aqueous 
solutions (Smedt, Demeester, & Hennink, 1999). The formed complexes also possess a 
positive charge that can interact with the cellular membrane to effectively achieve 
cellular uptake. 
 
Figure 2.1. Formation of a polyplex through electrostatic interactions between the positively charged 
polymer and negatively charged DNA. 
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Cationic polymers, in particular, are of great interest due to their potential 
advantages of easy production, stability, low immunogenicity and toxicity, and large 
DNA loading capacity (Ledley, 1995). Most cationic polymers contain a positively 
charged, protonated amine group that has electrostatic interactions with the negatively 
charged phosphate groups of DNA which allow for spontaneous formation of complexes, 
termed polyplexes (see Figure 2.1). When these positively charged polyplexes come in 
contact with the negatively charged cell membrane, they allow for increased DNA uptake 
that can substantially enhance transfection. The most widely used cationic polymer 
traditionally used in transfection studies are poly(ʟ-lysine) (PLL) (Wu & Wu, 1998), 
polyethyleneimine (PEI) (Abdallah et al., 1996), chitosan (Roy et al., 1999), poly(vinyl 
pyrrolidone) (Mendiratta et al., 1999), and polyamidoamide (PAMAM) (Qin et al., 
1998).  The main drawback to the use of these particular cationic polymers is their high 
cytotoxicity. This problem led to a parallel synthesis and screening of polymers by Barua 
et al. in 2009, to identify a cationic polymer that was biocompatible, degradable, and 
could effectively transport DNA to enhance transgene expression.  The study pointed to a 
one such polymer, 1,4C-1,4Bis (Figure 2.2), which was based on the monomers 1,4-
cyclohexanedimethanol diglycidyl ether (1,4C) and 1,4-bis(3-aminopropyl) piperazine 
(1,4Bis). The properties of this particular cationic polymer showed transfection 
enhancements much higher than the currently employed, pEI-25, in human prostate 
cancer cells and murine osteoblasts and thus was chosen as the polymer for all 
transfections in this study (Barua et al., 2009). 
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Figure 2.2. Monomers of the identified lead polymer 1,4C-1,4Bis. 
 
 
2.5 Cellular Barriers 
Efficacy of delivery is lost at each step of the gene transfection process, so it is 
important to understand the barriers within the cell and with cellular delivery in order to 
develop successful vectors for an efficient gene delivery method. While there are 
biological barriers prior to arriving at the target cell, including serum stability, cell-
specific targeting and route of administration, the primary focus of this investigation is on 
intracellular uptake of polyplexes as depicted in Figure 2.3.  
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Figure 2.3. The major cellular barriers that non-viral delivery methods must overcome to achieve transgene 
transfection: extracellular, intracellular trafficking, and transcriptional (adapted from Pack et al., 2005). 
 
2.5.1 Extracellular Barrier 
The first biological roadblock, once the vector reaches the target cell, is the 
extracellular barrier. The cell’s plasma membrane is comprised of a lipid bilayer, laden 
with integral proteins that selectively regulate molecules. Polyplexes tend to 
electrostatically interact with the cellular membrane, due to the positively charged 
cationic polymer and negatively charged glycoproteins, proteoglycans and 
glycerophosphates on the cell surface (Morille, 2008). The method of cellular uptake of 
INTRACELLULAR 
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polymer complexes seems to point towards non-specific adsorptive endocytosis followed 
by the clathrin-coated pit mechanism (Morille, 2008).   
Endocytosis is basically the invagination of the cellular membrane to transport 
extracellular molecules through the cytoplasm. Adsorptive endocytosis does not 
necessitate ligand-receptor interactions, but rather an unspecified physical adsorption of 
the complex at the cell surface (Jung et al, 2000). Complexes that are positively charged 
on the surface seem to undergo adsorptive endocytosis due to the electrostatic 
interactions (Merdan, Kopecek, & Kissel, 2002).  Clathrin-dependent endocytosis occurs 
at a specific domain in the cellular membrane where a clathrin protein is present 
(Mukherjee, Ghosh, & Maxfield, 1997). This area of the membrane is referred to as a 
clathrin-coated pit (Soenen et al., 2009).  Invagination of the plasma membrane at this 
particular point yields a vesicle that is clathrin-coated, but the vesicle tends to lose the 
sheath once it encounters other endosomes in the cytoplasm (Lungwitz et al. 2005).    
Endocytotic pathways are largely dependent upon cell membrane composition, 
surface charge, and size of the complexes (Rejman et al., 2004). This can make it hard to 
pinpoint the exact mechanism of the endocytotic uptake of polyplexes into the target cell. 
This complication is most likely attributed to the highly complicated and iterative events 
that sort molecules for transportation across the membrane to compartments within the 
cell (Jung et al., 2000).  
2.5.2 Intracellular Trafficking Barrier 
The next major hurdle for gene delivery is the intracellular trafficking barrier. 
Cytoplasmic trafficking also plays a large role in determining whether or not the 
complexes will be efficiently delivered. Once the polyplexes have been endocytotically 
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uptaken into the cell, microtubules fibers essentially carry the encapsulated endosomal 
vesicle down its ‘tracks’ (Rejman et al., 2004; Musch, 2004). There are two motor 
proteins, dynein and kinesin, that facilitate the direction the vesicles are carried within the 
cytoplasm (Suomalainen et al., 1999).  Dynein transports vesicles towards the nucleus 
(minus end of microtubules) while kinesin transports vesicles in the opposite direction, 
away from the nucleus and towards the cell membrane (plus end of microtubules). Bi-
directional movement can also occur with utilization of both motor proteins (see Figure 
2.4). In a particular study, when the microtubules were disrupted (using colchicine) or 
either of the motors was inhibited, transgene expression declined drastically (Drake & 
Pack, 2008). This finding suggests that microtubules and their motor proteins are 
essential to effective polymer-mediated gene delivery. 
 
Figure 2.4. Intracellular trafficking of endosome vesicle, containing polyplexes, along microtubule ‘tracks’ 
via kinesin motor, dynein motor, or switching between both. 
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Transportation problems associated with intracellular trafficking also occur with 
the need for DNA to escape the endosomes that encompass the polyplexes. The 
complexes generally follow the endolysosomal pathway that begins after endocytotic 
uptake, with the early endosomes, to the late endosomes, and finally ending in the 
lysosomes where the complexes have no effect in the cell (Merdan et al., 2002).  The 
problem is that polyplexes readily accumulate in the lysosomal compartment so the DNA 
is unable to reach the nucleus (Bieber et al., 2002).  Early endosomal escape is one way 
to achieve this, so the DNA can safely evade degradation by the lysosomal environment 
of nucleases and acidic pH (Barua, 2011). One proposed theory of how this can occur is 
by the ‘proton sponge hypothesis’ (Boussif et al., 1995). The proton sponge effect 
(shown in Figure 2.5) is theorized to inhibit acidification of endosomal pH by 
neutralization of protons pumped by an active membrane transporter, which results in 
chloride counter ions flooding into the endosomes, thus increasing the osmotic pressure 
that causes swelling, and eventually leads to bursting of the membrane (Akinc et al., 
2005;, Yamashiro, Fluss, & Maxfield, 1983; Al-Dosari & Gao, 2009).  This theory has 
been supported indirectly by a noticeable decrease of transfection efficacy of polyplexes 
containing the polymer, PEI, in cells containing drugs that prevented endosome 
acidification (Rittner et al., 2002; Kichler et all, 2001). Further support of this theory has 
been through the research by Sonawane and colleagues which revealed polymers with 
protonable amines induced substantial increases in chloride ion concentration and the 
number of endosomes containing polyplexes, while a polymer without protonable amines 
had no remarkable effects (Sonawane, Szoka, & Verkman, 2003).   
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Figure 2.5. Proton sponge theory where the proton pump draws protons inside the endosome (a), which 
results in an influx of chloride ions (b), followed by an increased osmotic pressure (c) that ultimately 
causes the membrane to burst and expel the contained polyplex (d) (adapted from Pack et al., 2005). 
 
2.5.3 Transcriptional Barrier 
After passing all the way through cell, the final obstacle for the pDNA to 
overcome is the transcriptional barrier. A vector carrying the pDNA may pass through the 
cellular membrane, evade lysosomal degradation, and have proper microtubule transport 
through the cytoplasm. But without the pDNA actually penetrating through the nuclear 
membrane, absolutely no expression can take place. This physical characteristic of the 
nuclear membrane seems to be one of the limitations since it is composed of nuclear 
pores that are quite small (~25 nm diameter). Thus the translocation of pDNA from the 
cytoplasm to the inside of the nucleus is size-dependent as depicted by the nuclear 
diffusion of oligonucleotides through nuclear pore complexes (NPC) (Elouahabi & 
Ruysschaert, 2005).  
The proposed mechanisms as to how polyplexes can cross the nuclear membrane 
are passive diffusion, active transport through DNA nuclear pores, or DNA entry during 
cell division (Elouahabi & Ruysschaert, 2005). The passive mechanism is effective for 
DNA fragments less than 250 bp via simple diffusion with no specific interactions 
(Mesika et al., 2005). The active transport method usually caters to larger DNAs (40 – 60 
kDa) through nuclear pore complexes (NPCs). The two possible mechanisms that 
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facilitate the active transport are cis-acting, DNA sequence-dependent transport and 
trans-acting mechanism requiring addition of peptides (Elouhabi & Ruysschaert, 2005). 
However, this active transport has not been a very efficient process to transport large 
DNA fragments across the nuclear membrane. Finally, there is the possibility of DNA 
translocation via simple diffusion during cell cycle division. It has been shown that there 
is higher transfection efficiency when cells are at or near the M phase (mitosis) of the cell 
cycle at the time of polyplex transfection (Brunner et al,, 2000; Brunner et al., 2002; 
Wilke et al., 1996; Tseng, Haselton & Giorgio, 1999; Mortimer et al., 1999). However, 
this is a variable factor with different types of polymers, even between linear and 
branched PEI, that was seen in the work conducted by Brunner and his group (Brunner et 
al., 2000).   Some cationic polymers, however, are independent of cell cycle stage in 
efficiently delivering transgenes to the nucleus. Since DNA cannot survive very long in 
the cytoplasm due to the presence of cytoplasmic nucleases, the uptake of pDNA into the 
nucleus is vital to effective gene expression, regardless of the method used (Lechardeur et 
al., 1999). 
2.6 Histone Deacetylase Inhibitors 
Histone deacetylases, (HDACs) are a type of enzyme that deacetylase lysine 
residues of histones, which remove charge-neutralizing acetyl groups from histone lysine 
tails, and subsequently cause the tight coiling of chromosomes around the histone 
proteins. Many HDACs have been discovered thus far and can be organized into four 
major classes (see Table 2.1).  All classes, except class III, are zinc-dependent HDAC 
(Marks & Xu, 2009). The main difference between class I and class II HDACs appear to 
be that class I seem to primarily work with cell survival and proliferation, while class II 
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work with specific tissues (Marks & Xu, 2009). What makes the HDACs 1 and 2 seem to 
be found exclusively in the nucleus, is the characteristic nuclear localization signal 
(NLS), but no nuclear export signal (NES) (de Ruijter et al., 2003).  Class II HDACs, 
however, possess both NLS and NES motifs, allowing for shuttling between cytoplasm 
and nucleus (Hess-Stumpp et al., 2007). Class III HDACs, also referred to as selective 
internal radiation therapies (SIRTs), are NAD+-dependent (Johnstone, 2002). Class IV 
HDACs have recently been discovered to show features of class I and II enzymes (Hess-
Stumpp et al., 2007).  
Table 2.1 Known HDAC classes, functions and relevant HDACi that inhibit their functions (adapted from 
Rasheed, Johsntone & Prince, 2007) 
Class Enzyme Location Function Relevant HDACi 
I HDAC1 
HDAC2 
Nucleus Participate in 
Sin3, NuRD 
and Co-REST 
complex 
SK-7041, SK-7068, MS-275, VPA, 
romidepsin butyrate, trapoxin, SAHA, 
TSA, PXD-101, LBH-589, LAQ-824, and 
MGCD-0103 
 HDAC3 Nucleus, 
rarely in 
cytoplasm 
Participate in 
SMRT, N-
CoR complex 
MS-275, VPA, butyrate, trapoxin, SAHA, 
TSA, PXD-101, LBH-589, LAQ-824 and 
MGCD-0103 
 HDAC8 Nucleus  VPA, butyrate, trapoxin, HDACI_B, 
TSA, PXD-101, LBH-589 and LAQ-824 
IIa HDAC4 Nucleus, 
Cytoplasm 
Interaction 
with 
SMRT/N-
CoR and co-
repressors 
BcoR and 
CtBP 
Romidepsin, VPA, butyrate, trapoxin, 
SAHA, TSA, PXD-101, LBH-589 and 
LAQ-824 
 HDAC5   VPA, butyrate, trapoxin, SAHA, PXD-
101, LBH-589, and LAQ-824 
 HDAC7   VPA, butyrate, trapoxin, SAHA, PXD-
101, LBH-589, and LAQ-824 
 HDAC9  Muscle 
differentiation 
VPA, butyrate, trapoxin, SAHA, PXD-
101, LBH-589, and LAQ-824 
IIb HDAC6 Cytoplasm Tubulin 
deacetylase 
Romidepsin, tubacin, SAHA, TSA, PXD-
101, LBH-589 and LAQ-824 
 HDAC10 Nucleus, 
Cytoplasm 
 Tubacin, SAHA, TSA, PXD-101, LBH-
589 and LAQ-824 
III SIRT1-7    
IV HDAC11 Nucleus, 
Cytoplasm 
 SAHA, TSA, PXD-101, LBH-589, LAQ-
824 and MGCD-0103 
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Histone deacetylase inhibitors (HDACi) are a new class of chemotherapeutic 
agents that inhibit HDAC action. Extensive research has shown that HDACs are related 
to repressed gene transcription and repressed expression of tumor suppressor genes 
(Marks et al., 2001; Carew, Giles, & Nawrocki, 2008). This is noted by the high HDAC 
levels that result in an increase of cancer cell proliferation, tight histone binding around 
DNA, and transcription inhibition (Marks et al., 2001). Since HDACs, HDAC1 in 
particular, are observed to be over-expressed in prostate cancer, they are an attractive 
target for anti-cancer gene therapy (Halkidou et al., 2004). While most HDACi in current 
clinical trials are being used for their primary enzymatic inhibition property, HDACi 
have also been found to have other mechanisms of action, based off of the structural 
diversity among the HDACi (Marks & Xu, 2009). HDAC can also bind to, deacetylate 
and regulate the activity of many other non-histone proteins , such as transcription factors 
(p53, E2F transcription factor (1E2F1), and nuclear factor-κB (NF-κB)) and other cellular 
proteins (α-tubulin, Ku70, and Hsp90) (Bolden, Peart, & Johnstone, 2006).  
Zinc-dependent HDACi include most of the HDACi in classes I, IIa, IIb, and V. 
There are generally three common structural characteristics in these molecules: a zinc 
binding moiety, an opposite capping group, and a straight chain alkyl, vinyl, or aryl linker 
that connects the two. It has been found that these functional groups interact with three 
conserved regions of the active site for certain zinc-dependent HDACi (Finnin et al, 
1999; Somoza et al., 2004; Vannini et al., 2004). The zinc ion facilitates amide 
hydrolysis and is found at the bottom of the catalytic pocket, the hydrophobic tunnel is 
penetrated by an acetyl-lysine substrate, and the channel opening contains the rim 
interaction with the hydrophobic capping group (Marks & Xu, 2009).   
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2.7 Combinational Therapy 
 Conventional cancer treatments that utilize only one therapy are rarely effective 
curative measures for the disease. However, when gene therapy is used in conjunction 
with traditional methods, outcomes of patients have shown clear benefits in clinical trials 
(O’Shaughnessy et al., 2002). While the use of cationic polymers to deliver exogenous 
DNA into cancer cells have proven to be somewhat effective by themselves, a 
combination with chemotherapeutic drugs is hypothesized to  synergistically enhance 
transgene expressions (Kasman, Lu, & Voelkel-Johnson, 2007). In this research, it is 
proposed that a combinational therapeutic approach that uses the novel cationic polymer, 
1,4C-1,4Bis and new class of chemotherapeutic agents (HDACi) can enhance transgene 
expression by altering intracellular trafficking and transcription regulation.  
17 
Chapter 3 
PREVIOUS STUDIES 
3.1 Cytoplasmic HDACi Investigations 
3.1.1 Introduction 
In a previous study conducted by Barua and Rege in 2010, the HDAC6 inhibitors, 
tubacin (cytoplasmic HDAC inhibitor) and Trichostatin A (TsA) (cytoplasmic and 
nuclear HDAC inhibitor) were evaluated for their combinational gene therapy 
effectiveness. Cytoplasmic HDACs, specifically HDAC6, deacetylates α-tubulin and 
regulates dynein motor transport on microtubules, thus mediating intracellular trafficking 
of cargo to the microtubular organizing center (MTOC), which had the potential to 
increase polyplex transport to deliver DNA for transcription (see Figure 3.1). 
 
Figure 3.1. Schematic of the uptake, sorting and localization of polyplex and quantum dots inside a cell. 
Intracellular localization of polyplexes at or away from the perinuclear recycling compartment 
(PNRC)/microtubule organizing center (MTOC) was equated to transfection in PC3-PSMA cells. (Barua & 
Rege, 2010). 
 
18 
3.1.2 Research Findings 
Tubacin acts as an inhibitor of this α-tubulin deacetylation, which results in more 
stable microtubules and better support within the cell, due to the increased dynein and 
kinesin motors for the microtubules. In this particular study, tubacin showed up to a 40-
fold transgene expression enhancement at 4 μM concentration and a polyplex ratio of 
25:1 (Figure 3.2) in PC3-PSMA cells. This is a significant enhancement, but the 10:1 
polyplex ratio only gave up to a 5-fold enhancement. This suggested that while mediators 
of intracellular trafficking have been known to enhance transgene expression, the overall 
enhancement may also be due to polyplex size, intracellular localization profiles, and 
corresponding basal levels of transgene expression.  Tubacin seems to have opposing 
motor activity when in a polyplex in cellular vesicles, resulting in more time for 
polyplexes or dissociated plasmid DNA to escape into the cytoplasm. This may have led 
to higher transgene expression as seen for the 25:1 polyplexes.   
The other HDACi evaluated in this study was Trichostatin A, a class I and II 
HDACi, which allows for inhibition of cytoplasmic and nuclear activity. In the 
cytoplasm, it acts similarly to tubacin in inhibiting HDAC6. In the nucleus, it acetylates 
histones to enhance transcription and transgene expression. TsA has shown to act in 
repositioning plasmid DNA towards sites that are transcriptionally active in the nucleus. 
In PC3-PSMA cells, TsA showed up to a 35-fold transgene expression enhancement at a 
250 nM concentration and a 25:1 polyplex ratio (Figure 3.2). Similar to tubacin, the 25:1 
polyplexes showed a significantly higher expression enhancement than the 10:1 polyplex 
ratio. These results seem to support the mechanisms mentioned above. However, other 
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mechanisms, such as promoter activation, may also play a role in the enhancement seen 
in the study. 
 
 
Figure 3.2. Transgene expression enhancement in PC3-PSMA cells transfected with pGL3 and treated with 
varied concentrations of the HDAC6 inhibitor a) Tubacin and b) Trichostatin A (Barua & Rege 2010). 
 
 
 
 
a) 
b) 
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3.2 Nuclear HDACi Investigation 
3.2.1 Introduction 
In a similar method to the previous studies for TsA and tubacin, this research 
involved the use of three nuclear HDACi’s in combination treatments with polymer-
mediated transcription to enhance transgene expression in PC3-PSMA prostate cancer 
cells.  For purposes of this investigation only, the names of the drugs were referred to as 
HDACi_A (a HDAC1, 2 and 3 inhibitor), HDACi_B (a HDAC1, 2 and 3 inhibitor), and 
HDACi_C (a pan-HDAC inhibitor). 
3.2.2. Research Findings  
PC3-PSMA cells were treated with different concentrations of HDACi_A, 
HDACI_B, and HDACi_C (0-1000 nM) at a 25:1 weight ratio of 1,4C-1,4Bis polymer 
and pGL3 polyplexes. Up to a 14-fold transgene expression enhancement was seen at a 
concentration of 500 nM (Figure 3.3) for HDACi_A, but because only n=2 experiments 
were carried out at this concentration, this was a result that needed additional study to 
verify its validity. The next highest enhancement at 1000 nM for HDACi_A was 
approximately 8-fold, whereas HDACi_B and HDACi_C showed only up to a 4-fold 
enhancement. While there was some noticeable enhancement with the combination 
therapy, it was not as significant as previous studies showed with TsA (35-fold) and 
tubacin (40-fold). HDACi_C and HDACi_B both showed very little enhancement, 
making them less promising chemotherapeutic drugs to use in further research. However, 
despite results showing little synergistic enhancement in PC3-PSMA cells, compared to 
prior studies, the HDAC1, 2 and 3 inhibitor (HDACi_A) showed the most potential as the 
lead molecule to for additional studies with polymer-mediated transgene delivery.  
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Figure 3.3. Transfection of PC3-PSMA cells using luciferase gene and 1,4C-1,4 Bis polymer in presence of 
HDACis: HDACi_A, HDACi_B, and HDACi_C. The luciferase gene containing pGL3 DNA of 200ng and 
the polymer:pGL3 DNA ratio of 25:1 (w/w) were used. Luciferase expression was measured as RLU/mg 
protein using luciferin and BCA, giving the values with respect to no treatment for the corresponding drug 
(0 nM and in presence of polyplexes for samples of same color). HDACi_A at 500 nM was carried out only 
as n = 2.  Data was statistically significant for all of HDACi_B, HDACi_C, and HDACi_A at 500 nM 
concentrations (p < 0.05 with Bonferroni correction). 
 
Cell cytotoxicities for all the HDACi molecules tested were within an acceptable 
range as depicted in Figure 3.4. HDACi_C displayed a slightly higher cell death (up to 
40% for 1000 nM concentration) than the rest, which may have decreased the RLU 
expression seen at this concentration, but not significantly enough to reconsider the 
results. HDACi_B had up to a 25% cell death, which would very unlikely skew the RLU 
expressions either. With a less than 10% cell death across all concentrations, HDACi_A 
made itself a better candidate for future studies as it displayed the lowest cytotoxic levels, 
even at the higher concentrations.   
The large error in most of the HDACi_A results and 1000 nM HDACi_B 
concentration results could have been attributed to the luciferin used in these 
experiments. Probably the most notable source of this error was due to the D(-)-Luciferin 
  
   
*      *   
*  
 *   *     *   *  
 *   
*   *   
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powder to make 30 mg/mL aliquots re-suspended in 1X PBS, instead of dimethyl 
sulfoxide (DMSO). The luciferin powder was only soluble in DMSO and slightly soluble 
in water, and by re-suspending in 1X PBS, the powder could never fully dissolve. Thus, 
the luciferin was probably distributed unevenly in the 15 mL aliquot tubes used in 
preparing a luciferin mixture with medium prior to luciferase expression reading on the 
plate reader. Not only were the tubes probably unevenly distributed with the powder, the 
wells that were read may also have contained uneven amounts, giving variable readings 
from well to well. This error could have been prevented and subsequent experiments may 
have shown less variability in the results.  
The other possible source of error could be due to the protocol used for the 
luciferin preparation. Previous studies in the lab had used a luciferase assay which had a 
standardized protocol to measure luciferase expression. This experiment, however, used 
new luciferin powder assay system, instead of the luciferase assay and buffer system 
previously employed. While the protocol used for measuring luciferase expression was 
thought to have been reliable, it was a new procedure that had not been standardized. 
This may have also contributed to the variability noted in the RLU expressions for the 
HDACi used. 
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Figure 3.4. Cell viability of PC3-PSMA cells, measured in percentages, when treated with the labeled 
HDACi. The concentrations represent those of the drugs with a 25:1 polyplex ratio. a) HDACi_A displayed 
less than 10% cell death for all concentrations,  b) HDACi_B showed up to 25% cell death for the highest 
concentration (1000 nM) and c) HDACi_C displayed up to 40% cell death for the highest concentration 
(1000 nM), which makes the cytotoxicities of each drug acceptable. An ANOVA analysis showed 
statistical significance in the data for HDACI_B and HDACi_C, but not HDACi_A (*p < 0.05). 
a) 
b) 
c) 
 *  
 *  
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3.3 Conclusions 
In both studies, an attempt was made to achieve synergistic enhancement of 
transgene expression through polymer-mediated gene delivery with the use of HDACi. 
The cytoplasmic HDACi were novel findings that spurred the interest in studying the 
possibility of similar effects in nuclear HDACi. This nuclear HDACi study, 
unfortunately, yielded results that were less than extraordinary. Initial findings of the 
small molecule, HDACi_A, seemed to be the best candidate to pursue for initial studies, 
despite its relatively low synergistic enhancement, compared to the 40-fold enhancements 
seen in Tubacin and TsA. However, with its highest enhancement of 14-fold, it was still a 
promising candidate to evaluate further.  
The data for HDACi_B and HDACi_C showed little enhancement and large 
sources of error which are likely attributed to a luciferin protocol that is not effective and 
the resuspension error made with the luciferin powder. This inconsistency of protocol 
made the use of luciferin powder not very attractive. Thus, a switch back to luciferase 
assay for expression readings was made for the following study.  
With these findings, a nuclear HDACi lead drug was identified and an alteration 
in assay system to evaluate further findings was made. The following chapters discuss 
further the investigation that used HDACi_A as part of combinational therapy in 
polymer-mediated transgene delivery in PC3-PSMA cells.  
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Chapter 4 
MATERIALS AND METHODS 
4.1 Cell Culture 
The PC3-PSMA (Prostate Specific Membrane Antigen) human prostate cancer 
cell line was a generous gift from Dr. Michel Sadelein (Memorial Sloan-Kettering Cancer 
Center, New York, NY). Cells were cultured at 37 °C and in a humidified 5% CO2
4.2 Purification of Plasmid DNA 
 
incubator in RPMI-1640 medium (HyClone®, UT) containing 10% heat-inactivated fetal 
bovine serum (FBS) and 1% peni-strep (100 units/mL penicillin and 100 μg/mL 
streptomycin). 
 The pGL3 control vector (Promega Corp., Madison, WI) is a plasmid DNA that 
encodes for the modified firefly luciferase protein under control of an SV40 promoter. 
The pGL3 was added to a culture of DH5α Escherichia coli (XL1 Blue) and incubated 
overnight (16 h, 37 °C, 225 rpm) in 150 mL of Terrific Broth (MP Biomedicals, LLC) 
containing 150 μg/mL antiampicillin (Research Products International, Corp.). Cultures 
were centrifuged at 6000 rcf at 4ºC for 15 minutes and the QIAprep Maxiprep Kit 
(QIAGEN Inc., Valencia, CA) protocol was followed to purify the plasmid DNA. 
Concentration and purity of the plasmid DNA was based on absorbance at 260 and 280 
nm, which was determined via a NanoDrop Spectrophotometer (ND-1000; NanoDrop 
Technologies). Plasmid DNA within the acceptance range of 1.8 – 2 of the 260/280 nM 
ratio were the only DNA used for experiments in this research. Plasmid DNA was stored 
at -20 ºC and thawed on ice upon use. 
 
26 
4.3. Transfection Protocol 
 In a 24-well plate, PC3-PSMA cells were seeded at a density of 50,000 cells/well 
in 500 μL serum-containing growth medium (RPMI-1640 medium with 10% FBS and 
1% peni-strep) and allowed to attach overnight. Growth medium was aspirated from the 
24-well plate and replaced with 500 μL serum-free medium (RPMI-1640 and 1% peni-
strep).  The HDACi was added in 1 μL amounts of specified concentrations to the cells. 
Polyplexes of 1,4C-1,4Bis (1,4-cyclohexanedimethanol diglycidyl ether-1,4-bis(3-
aminopropyl) piperazine) polymer and pGL3 control vector in specified polymer:pDNA 
w/w ratio (200 ng pGL3 concentration) were prepared by adding the polymer to DNA in 
1.5 mL centrifuge tubes, then incubated at room temperature for 20 min. The resulting 
polyplexes were added to the cells for 6 h. Serum-free medium was pipetted out of the 
wells and replaced with 500 μL serum-containing growth medium. Another 1 μL of the 
HDACi drug at the varied concentrations was added to the corresponding wells. Cells 
were incubated for 48 h at 37 °C and 5% CO2
4.4 Luciferase Assay 
. 
Following ~48 h incubation of treated cells, medium was collected in 1.5 mL 
centrifuge tubes and washed with 150 μL of 1X phosphate buffered saline (PBS: 10mM 
Na2HPO4, 140mM NaCl, pH ~7.4). Each well was then treated with 150 μL of 1X cell 
lysis buffer reagent (Promega) for no longer than 2 min, but long enough to detach cells. 
Content from centrifuge tubes was then added back to lysate.  For samples that did not 
need to be diluted, 25 μL of the cell suspension was put into a 96 well non-sterile half 
area white plate in triplicates. For samples needing dilution, 100 μL of the cell suspension 
was put back into the centrifuge tubes and had 900 μL of nanopure water added to dilute 
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10X. If further dilution was still needed, 50 μL of this 10X dilution was taken into new 
1.5 mL centrifuge tubes in order to dilute 200X. With either dilution, 25 μL was taken 
and placed in the 96-well non-sterile half area white plate. Luciferase Glo Kit (Promega) 
was thawed at RT and mixed via vortexing, and then 50 μL was added to white plate as 
quickly as possible. The samples were read by Bio-Tek Synergy 2 plate reader 
immediately with excitation 360/40 filter plugged and emission 528/20 filter holed. 
Protein contents of each well were measured by Pierce BCA Protein Assay Kit (Pierce 
Biotechnology, Rockford, IL). The relative luminescence values (RLU) were normalized 
from these measured protein contents for each sample. 
4.5 Enhancement of Polymer-mediated Transgene Expression Using HDACi 
 PC3-PSMA cells were treated with 1 μL HDACi_A (0 – 2000 nM) at one of the 
six w/w ratios (1:1, 5:1, 10:1, 20:1, 25:1) of 1,4C-1,4Bis polymer and pGL3 plasmid 
DNA polyplexes. Following the ~48 h incubation period in the presence of the 
HDACi_A, PC3-PSMA cells were washed, lysed, and re-suspended in the medium, and 
prepared as the luciferase assay describes in section 4.4.  Transgene expression was 
reported as fold increase in normalized RLU/mg protein relative to no treatment (cells in 
the presence of polyplexes but no HDACi). 
4.6 Statistical Analysis 
All values are expressed as the mean ± one standard deviation (S.D.). All 
experiments were carried in at least triplicates, unless mentioned otherwise. A two-tailed, 
paired Student’s t-test was used to analyze the significance of the difference between the 
control and each experimental test condition (α = 0.05 and 0.005), with a Bonferroni 
correction (α/29 comparisons), giving the equivalent of α = 0.00172 and 0.000172, 
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respectively. ANOVA was run for cell viability data to test statistical significance. All 
analyses were conducted using Excel 2003. 
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Chapter 5 
RESULTS AND DISCUSSION 
A combinational approach was taken to investigate the effects of a lead nuclear 
HDACi and lead polymer for a non-viral gene delivery system. It was hypothesized that 
an HDACi that works inside the nucleus could overcome transcriptional barriers to 
enhance transgene expression in prostate cancer. In this research, four different 
polymer:pDNA weight ratios were used to deliver the plasmid DNA, pGL3, into PC3-
PSMA cells treated with varied concentrations of HDACi_A (a nuclear HDACi). The 
efficacy of the transfections were evaluated by reading luminescence (relative 
luminescence units or RLU) due to expression of the luciferase protein and normalized to 
the corresponding protein content of the sample. 
 The results from the transfections (see Figure 5.1) showed that the 20:1 
polymer:pDNA ratio was the most effective compared to the other polyplex ratios tested. 
The trend seems to show little increase in transfection efficacy between 1:1 and 10:1, a 
significant spike at 20:1, and a decrease with 25:1. This could be indicative of a possible 
size correlation with the transgene efficacy, but a size-zeta potential analysis would need 
to be conducted to prove this. Especially interesting would be to see if the 20:1 polyplex 
ratio is well within the endocytotic limits compared to the other ratios.  
At this 20:1 polyplex ratio, the two highest HDACi_A concentrations tested (1, 2 
μM) gave up to a 9-fold enhancement, with 750 nM HDACi_A not too far behind with 
around an 8-fold enhancement.  All other combinations of polyplex ratio and drugs were 
of little interest with less than 5-fold enhancements. 
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While the standard deviations for the 20:1 polyplexes were higher than most, the 
1000 and 2000 nM concentrations were statistically significant as denoted by the 
Bonferonni correction, which takes into account the entire sample amount. The 
enhancement at the higher HDACi_A doses is consistent with the drugs effectiveness 
seen in clinical trials at the micromolar scale (Bolden, Peart, & Johnstone, 2006). 
Additional experiments are needed to further understand the reasoning behind this 
enhancement. 
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Figure 5.1.  Luciferase expression in PC3-PSMA cells treated with HDACi_A using different 
polymer:pDNA weight ratios. Enhancement shown is related to no treatment (0 nM HDACi_A) but in the 
presence of polyplexes. Luciferase activity was measured as RLU/mg protein using means ± standard 
deviation (n ≥ 3). Statistical significance of * and ** indicated p < 0.05 and p < 0.005 (with Bonferroni 
correction), respectively using two-tailed, paired Student’s t-test.  
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 *  ** 
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 ** 
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 Actual luminescence expression values (RLU/mg protein) showed an increasing 
trend with increasing polyplex ratios (Table 5.1). This finding may support that these 
larger delivery devices may be more effective at overcoming biological barriers that are 
characteristic on non-viral delivery. One possibility is that the larger molecule increases 
endosomal escape due to proton sponge effect, since there is more cationic polymer to 
buffer against the acidic endosomal environment. However, additional studies would 
need to be conducted to verify this hypothesis.   
Table 5.1 Normalized RLU/mg protein with S.D. x 103
 
 of polyplex ratios at the six drug concentrations 
RLU/mg protein ± S.D. x 10^3 
HDACi_A 
Concentration 
(nM) 
1:1 plx 10:1 plx 20:1 plx 25:1 plx 
0 0.04 ± 0.03 3.0 ± 2.0 51.0 ± 75.0 4000.0 ± 800.0 
100 0 ± 0 3.8 ± 1.1 90.0 ± 72.0 6200.0 ± 870.0 
250 0.06 ± 0.01 7.0 ± 7.0 120.0 ± 101.0 6000.0 ± 240.0 
500 0.03 ± 0.03 9.6 ± 6.2 180.0 ± 145.0 9500.0 ± 3100.0 
750 0.07 ± 0.1 7.3 ± 3.2 270.0 ± 145.0 11000.0 ± 530.0 
1000  8.5 ± 8.0 250.0 ± 230.0 12000.0 ± 1000.0 
 
 Standard deviations were fairly high for nearly all polyplex and drug 
combinations, but more so at the 20:1 polyplex ratio. The reason behind this could be due 
to the larger sample size taken for 20:1 (n = 12) compared to the other polyplexes (n = 3 
for 1:1 and n = 6 for 10:1 and 25:1). Additionally it has been witnessed in our laboratory 
that plasmid DNA, from different purifications has a variation in expression levels. Half 
the transfections at 20:1 used pGL3 were from one recently made stock and the other half 
from one from a year-old stock stored at -20ºC. Interestingly, though, it was noted that 
while the recent plasmid DNA gave higher luminescence values, it also gave lower 
32 
transfection enhancements. Further speculation is needed to understand the reason behind 
this, and may spur additional experiments to compare different plasmid DNA stocks.  
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Chapter 6 
CONCLUSION 
 The goal of this research was to evaluate the effectiveness of combinational 
therapy with a specific nuclear HDACi and polymer-mediated transgene delivery on 
transgene expression. Prior studies with HDACi that inhibit functions of HDAC in the 
cytoplasm (tubacin and TSA) have shown up to 40-fold enhancement over polymer 
delivery, alone. This same principle was thought to have similar results with HDACi that 
are found to work in the nuclear realm.  
A preliminary screening of a few potential molecules yielded one HDACi that 
showed promise for further studies. This chemotherapeutic agent, HDACi_A, showed up 
to a 9-fold enhancement in PC3-PSMA cells at a 20:1 polymer:pDNA ratio for doses of 1 
and 2 μM. This dose range was consistent with effective doses used in current clinical 
trials. It is hypothesized that the 20:1 polyplex ratio may have a size-correlation with 
transfection efficacy. Additional studies still need to be conducted to further understand 
the reason behind this enhancement.  
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Chapter 7 
FUTURE WORK 
7.1 Cell Cytoxicity 
To further analyze the effect of HDACi_A on polymer-mediated transgene 
delivery, it is important to collect data on cell cytotoxicity, since this is an important 
factor in achieving an effective gene delivery system. Without acceptable cell viability, 
the combinational therapy proposed would not be useful in clinical applications. These 
experiments would be conducted for all combinations of polyplex ratios and drug 
concentrations in the same method used in previous studies, via MTT assay.  
7.2 Size and Zeta Potential 
Another important part of this study will be to collect data on size and zeta 
potential in order to ensure a correlation to the obtained luciferase results.  This 
information will give further insight as to possible size barriers that could decrease the 
uptake and efficiency of transgene expression. 
The methods for determining the polyplex size and zeta potential would be 
through the use of dynamic light scattering (DLS) via Malvern Zetasizer Nano Series 
(Malvem Instruments Inc., Westborough, MA). Polyplexes are incubated at R.T. for 20 
min at 0.4 μg/ml pDNA at the w/w ratios used in the transfection study in 1X PBS.  
7.3 Additional Cell Lines 
Additional cell lines would need to be transfected with the same polyplexes and 
HDACi to evaluate the effectiveness of the combinational effects that can transcend only 
PC3-PSMA.  This is essential because prostate cancer cell lines have shown to have 
various outcomes due to phenotypic differences (Barua & Rege, 2009). Also, an 
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investigation of breast cancer and pancreatic cell lines could open up additional research 
that could prove more effective. An initial dose response would be conducted for each 
cell line to establish the scale for HDACi_A concentrations (such as nano- or micro-
molar). Then the transfections would be carried out as discussed in section 4.3 with same 
polymer and plasmid DNA at the same polyplex w/w ratios and the ascertained 
HDACi_A concentrations from the dose response. 
7.4 Alternative Novel Polymer 
 In the laboratory, polymer synthesis has been conducted to find a new lead 
polymer that is highly efficient as a vector for gene therapy. One such polymer has been 
discovered and has shown significant enhancements in transgene expression. Use of this 
polymer with HDACi_A could have a possible synergistic effect. The same method as 
depicted in section 4.5 would be used to evaluate the best combination of polyplex ratio 
and drug concentration. 
7.5 Use with TRAIL Gene 
Finally, to test the effectiveness in an actual cancer therapy, the lead polyplex 
ratio and drug concentration obtained in this study, with the least cytotoxicity, would 
need to be tested with the tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL) gene. Past studies have shown effective use of HDACi that enhance the TRAIL 
gene in LNCap prostate cancer cell line using viral methods (Kasman, Lu, & Voelkel-
Johnson, 2007). The combinational therapy used in this research could have similar 
outcomes in PC3-PSMA cell lines with use of TRAIL.  
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Figure A1. Proposed schematic of polymerization of 1,4C-1,4Bis polymer based on the ring opening of the 
diglycidyl ether by the amine (adapted from Barua et al., 2009). 
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Table A1. Characteristics of 1,4C-1,4Bis compared to pEI-25 (Barua, 2011). 
 1,4C-1,4Bis pEI-25 
Mn  3.9  (kDa) 10  
Mw 23.5  (kDa) 25 
Polydispersity 5.96 2.5 
Size (nm) 10:1 plx ratio 154.5 ± 13 190.7 ± 6.3 
25:1 plx ratio 244.8 ± 17  261.7 ± 9.3 
Zeta Potential (mV) 10:1 plx ratio 22.8 ± 2.7 20.7 ± 2.2 
25:1 plx ratio 27 ± 4.3 25.7 ±1.6 
 
